Krystal looks to Phase III as stock soars on data for gene therapy

With its lead gene therapy showing efficacy in healing wounds in a rare skin condition, Krystal has seen its market cap multiply sixfold since its 2017 IPO as it now looks

Read the full 314 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE